ProQR Announces Results for the First Quarter of 2018
ProQR Therapeutics N.V. - Ordinary Shares (PRQR)
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
proqr.com
Company Research
Source: GlobeNewswire
Key updates Eight out of twelve patients have been enrolled in a Phase 1/2 clinical trial of QR-110 in adults and children with LCA 10. Interim data are expected in the second half of 2018, with full data expected during 2019.ProQR and Galapagos N.V. entered into a research collaboration to apply the Axiomer® RNA editing technology to fibrosis targets selected by Galapagos.Partnership with Foundation Fighting Blindness where ProQR will receive up to $7.5 million in funding for the development of QR-421a for the vision loss associated with Usher syndrome type 2A.ADAR A-to-I RNA editing expert Dr. Peter A. Beal was appointed to ProQR’s scientific advisory board. LEIDEN, the Netherlands, May 09, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced results for the first quarter of 2018. “We made strong pro
Show less
Read more
Impact Snapshot
Event Time:
PRQR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRQR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRQR alerts
High impacting ProQR Therapeutics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRQR
News
- ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024GlobeNewswire
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual MeetingGlobeNewswire
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio [Yahoo! Finance]Yahoo! Finance
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP PortfolioGlobeNewswire
- ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc. from $1.80 to $2.00. They now have a "buy" rating on the stock.MarketBeat
PRQR
Earnings
- 11/7/23 - Miss
PRQR
Sec Filings
- 4/23/24 - Form 6-K
- 4/19/24 - Form 6-K
- 3/13/24 - Form 20-F
- PRQR's page on the SEC website